
CLAIMS

1. Composition comprising at least one 7β-hydroxycholesterol derivative and a lipid vehicle, excluding a lipid vehicle consisting of lipid vesicles formed from one or more lipid layer(s) or consisting of phospholipids in the non-liposomal form, wherein said lipid vehicle comprises an oil or a mixture of oils, in which the 7β-hydroxycholesterol derivative corresponds to formula (I)



(I)

in which:

- A represents

a -C(O)R_1 group in which R_1 is a saturated heterocycle comprising 5 to 14 members and including 1 or 2 heteroatoms, unsubstituted or substituted with at least one linear or branched C_1-C_6 alkyl;

or a -$(R_2)_n$- group in which R_2 is an amino acid residue bound by its C-terminal end and n= 1 to 3, each of the R_2 being identical or different, in which the N-terminal end of said amino acid may be substituted with a -C(O)R_3 group in which R_3 is a; a C_6-C_{14} arylalkyloxy group,

- B represents a -C(O)R_4 group, in which R_4 is a linear or branched C_1-C_{12}, preferably C_1-C_6, alkyl, or R_4 represents OR_5, in which R_5 is a linear or branched C_1-C_{12}, preferably C_1-C_6, alkyl.

2. Composition according to claim 1, in which said vehicle comprises at least one lipid other than a phospholipid.

3. Composition according to claims 1 or 2, characterized in that it is in a form suitable for administration by the oral route.

4. Composition according to any one of claims 1 to 3, characterized in that the compound of formula (I) is in solution in said lipid vehicle.

5. Composition according to any one of claims 1 to 4, in which said lipid vehicle comprises a vegetable oil or a mixture of vegetable oils.

6. Composition according to any one of claims 1 to 5, in which said lipid vehicle comprises a vegetable oil selected from argan oil, avocado oil, linseed oil, sunflower oil, palm oil, cabbage palm oil, coconut oil, grapeseed oil, black mustard oil, poppy seed oil, shea butter oil, sweet almond oil, soya oil, peanut oil, cottonseed oil, sesame oil, olive oil, maize oil, cocoa oil, castor oil, Moringa oil (or Ben oil), rapeseed oil, annatto oil, wheatgerm oil, safflower oil, walnut oil, hazelnut oil, turnip rape oil or mixtures thereof.

7. Composition according to any one of claims 1 to 6, in which said lipid vehicle is argan oil.

8. Composition according to any one of claims 1 to 7, characterized in that, in formula (I), A represents a $-C(O)R_1$ group in which R_1 is a saturated heterocycle comprising 5 members and including 2 oxygen atoms, substituted with at least one linear or branched C_1-C_6 alkyl.

9. Composition according to any one of claims 1 to 8, characterized in that, in formula (I), B represents a $-C(O)R_4$ group in which R_4 is a linear or branched C_1-C_6 alkyl, or R_4 represents OR_5, in which R_5 is a linear or branched C_1-C_{12}, preferably C_1-C_6, alkyl.

10. Composition according to any one of claims 1 to 8, characterized in that, in formula (I), B represents an acyl group in which the alkyl group is C_1-C_6 or an alkoxycarbonyl group in which the alkyl group is C_1-C_6.

11. Composition according to claim 1 to 7, 9 or 10 , characterized in that, in formula (I), A represents:

- a $-(R_2)_n-$ group in which R_2 is an amino acid residue and n = 2; or
- a $-(R_2)_n-$ group in which R_2 is an amino acid residue, n= 2 and the N-terminal end of said amino acid is substituted with an arylalkoxycarbonyl group, in particular benzyloxycarbonyl; or
- an alanyl radical bound to a glycinyl radical, optionally substituted at its N-terminal end with an arylalkoxycarbonyl group, in particular benzyloxycarbonyl; or
- a methionyl radical bound to a glycinyl radical, optionally substituted at its N-terminal end with an arylalkoxycarbonyl group, in particular benzyloxycarbonyl, and

- B is as defined in claim 1.


12. Composition according to any one of claims 1 to 11, in which the 7β-hydroxycholesterol derivative is selected from the compounds of formula (I) in which:

- A is a 3-benzyloxycarbonyl-glycinyl-alanyl group and B is a tert-butoxycarbonyl group, or

- A is a 3-benzyloxycarbonyl-glycinyl-alanyl group and B is an acetyl group, or

- A is a -C(O)R_1 group in which R_1 is a 2,2-dimethyl-1,3-dioxolane group and B is a tert-butoxycarbonyl group.

13. Composition according to any one of claims 1 to 10 or 12, in which the 7β-hydroxycholesterol derivative is a compound of formula (I) in which A is a -C(O)R_1 group in which R_1 is a 2,2-dimethyl-1,3-dioxolane group and B is an acetyl group, of formula



.

14. Composition according to any one of claims 1 to 13, in which the content of compound of formula (I) is from 0.1 to 3.5% (w/v) of the total volume of the composition.

15. Composition according to any one of claims 1 to 14, characterized in that the content of compound of formula (I) is from 1 to 35 mg/ml, preferably 30 mg/ml.

16. Composition according to any one of claims 1 to 15, characterized in that the content of lipid vehicle is from 90 to 99% (v/v) of the total volume of the composition.

17 Pharmaceutical composition comprising a composition according to any one of claims 1 to 16.

18. Pharmaceutical composition according to claim 17, characterized in that it is in a form suitable for administration by the oral route.

19. Method for preparing a composition according to any one of claims 1 to 14, comprising the following steps:

- preparing a mixture containing the 7β-hydroxycholesterol derivative of formula (I) as defined in any one of claims 1or 8 to 13, a lipid vehicle and a co-solvent,
- optionally adding an antioxidant and
- if applicable, evaporating the co-solvent.

20. Method according to claim 20, wherein the lipid vehicle is as defined in any one of claim 2 or 5 to 7.

21 Composition according to any one of claims 1 to 18, for use in the treatment of a neoplastic pathology or a malignant haemopathy.

22. Composition for use according to claim 21, in which the neoplastic pathology is glioblastoma multiforme.